fashion -WSS

fashion

author：explore 2025-08-21 08:27:08 - browse：4

A purple number 3 with an eye is surrounded by smaller, black number 3s on a green background — 3 to watch coverage from STAT — Christine Kao/STAT

Every winter, like Punxsutawney nobles, biotech’s many thought leaders gather for the J.P. Morgan Healthcare Conference to pick apart the year that was and prognosticate about the one to come. The consensus, in good markets and bad, is almost always cautious optimism for boom times ahead, a prediction that in recent years has had groundhog-level accuracy.

But after two years of steady decline, 2024 might finally prove them right. Biotech is on the upswing, driven by the rise of some headline-grabbing medicines, the advance of cutting-edge technologies, and a few reminders that big drug companies are still willing to pay billions of dollars for small ones.

Here are three major themes that we expect to drive the news in 2024 and determine whether biotech’s comeback is a sustainable trend or an interest-rate phenomenon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： How one patient went off dialysis — and others can too

leisure time

WSS

Health tech startups drop sharply from 2021 highs

Would Medicare drug price negotiations stall in a shutdown?

FDA advisers vote against ALS treatment from BrainStorm

A letter from the executive editor: STAT UnitedHealth investigation

Kaiser Permanente unions announce official strike date

FDA reorg will put new emphasis on investigations, sources say

hotspot

fashion

focus

Continuity nursing helped my family in our darkest PICU moments

Ventyx halts psoriasis drug development after lackluster trial results

United colonoscopy coverage change 'may cost lives,' doctors say

Ohio still needs to do more to protect the right to abortion

Medicare details structure of new drug price negotiation program

Paxlovid should be available without a positive Covid test

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Type 2 diabetes prevention programs work at large scale: study

Cancer drug shortages should be causing more outrage

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

focus

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Researchers use wearables data and AI to predict preterm birth risk

Researchers use wearables data and AI to predict preterm birth risk

After decades in use, heart stents finally beat placebo

STAT Virtual Event: How to Increase Diversity in Clinical Trials

leisure time

hotspot

leisure time

hotspot